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Abstract
Human cytomegalovirus (HCMV), a member of the Betaherpesvirinae sub-family of Herpesviridae family, is a
widespread pathogen that infects a majority of the world’s population by early adulthood. In individuals whose
immune systems are immature or weakened, HCMV is a significant pathogen causing morbidity and mortality.
There is no effective vaccine and only limited antiviral treatments against HCMV infection to date. A possible target
for novel antiviral treatments is the HCMV proteins that localize to the tegument of the virion, since they play
important roles in all stages of the viral life cycle, including, viral entry, gene expression, immune evasion, assembly,
and egress. The most likely tegument protein candidates are pp65 (immune evasion), pp71 (gene expression), and
pp150 and pp28 (assembly and egress). Although the subcellular localization of these proteins has been identified
during HCMV infections in vitro, their localization patterns have not been determined when each protein is
expressed individually in living cells. Thus, the objective of this review is elucidate the HCMV tegument as well as
present current research findings concerning the subcellular localization of the tegument proteins pp65, pp71,
pp150, and pp28 as fusions to one of several fluorescent proteins.
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Human cytomegalovirus significance
Human cytomegalovirus (HCMV) is a member of the
Betaherpesvirinae sub-family of Herpesviridae. It is a wide-
spread pathogen that infects a majority of the world’s
population by early adulthood [1]. In fact, by the age of 40,
between 50 and 85% of adults are infected by HCMV [2].
The virus establishes a life-long infection with some cells
being latently infected, a state where the virus has the abil-
ity to lie dormant within a cell, while others are persis-
tently infected, where the infection cannot be cleared from
an organism and there is intermittent shedding of infec-
tious virions [3]. Immunocompetent individuals, who can
develop a strong immune response, typically display no
symptoms of infection [4]. However, in individuals whose
immune systems are immature or weakened, such as
organ transplant and AIDS patients, HCMV is a signifi-
cant pathogen causing morbidity and mortality [5]. Symp-
toms in these individuals typically consist of spiking fever,
leucopenia (decrease in white blood cells), malaise,
hepatitis, pneumonia, gastrointestinal disease and/or reti-
nitis (inflammation of the retina) [4]. HCMV is also
responsible for approximately 8% of infectious mononu-
cleosis cases [6] and is the leading viral cause of birth
defects often causing deafness and mental retardation in
the fetus if a woman is infected during pregnancy [7].
HCMV has been implicated in playing a role in inflam-
matory and proliferative diseases, including certain cardi-
ovascular diseases and cancer [8]. Epidemiological and
pathological studies have espoused a strong link between
HCMV and atherosclerosis [8]. Several mechanisms have
been proposed in which HCMV could influence the
development of athersclerotic vascular abnormalities [9].
A proposed role of HCMV in the pathogenesis of athero-
sclerosis involves the reactivation of a latent HCMV
infection followed by virus-induced enhancement of vas-
cular inflammation and damage through smooth cell pro-
liferation, uptake of low-density lipoproteins by smooth
cells, neointimal formation (thickened arterial layer via
cell migration and proliferation), and narrowing of the
vessel lumen [9].
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that inhibit viral replication exist but are ineffective due to
high toxicity, low bioavailability, and the development of
drug-resistant virus strains [8,10]. The primary antiviral
agents used to treat HCMV infections in patients with an
impaired immune system are ganciclovir, foscarnet, and
cidofovir [9]. These drugs have improved the survival and
quality of life of immunocompromised individuals suffer-
ing from HCMV, but they are far from ideal due to major
hematologic, renal, and neutropenia toxicity [9]. There-
fore, the lack of an effective treatment for HCMV infec-
tions, especially in immunocompromised individuals, has
resulted in intense study for the identification of proteins
and processes that could be targeted by novel antiviral
treatments [8].
Human cytomegalovirus structure and life cycle
HCMV has the prototypical herpesvirus virion struc-
ture (Figure 1) and the replication cycle has a well con-
trolled cascade of gene expression [9]. The virion has
an icosahedral protein capsid that contains the 235-kb
double-stranded DNA. The capsid is surrounded by a
proteinaceous tegument and an outer lipid envelope
[1]. Virions gain entry into a cell through a membrane
fusion event involving the outer membrane of the cell
and glycoproteins on the lipid envelope of virions.
Once the fusion of these two membranes occurs, the
DNA-containing protein capsid and the tegument pro-
teins are released into the cell [11].
The gene expression pattern follows a similar cascade as
used by other herpesviruses as reviewed in Kalejta (2008)
[12]. During the lytic infection, viral immediate-early genes
are expressed [8]. The expression of these genes results in
the production of viral immediate-early proteins that mod-
ulate the host cell environment and stimulate the expres-
sion of viral early genes [1]. The viral-immediate early
genes produce proteins that are responsible for replicating
the double-stranded viral genomic DNA; after DNA repli-
cation, these immediate-early genes turn on the expression
of viral late genes [1]. The viral late proteins are mainly
structural components of the virion that assist in the
assembly and egress of newly formed viral particles [1].
Figure 1 A cartoon depicting the structure of the HCMV virion. (Image obtained from (http://www.virology.net/big_virology/bvdnaherpes.
html) courtesy of Dr. Marko Reschke in Marburg, Germany).
Tomtishen III Virology Journal 2012, 9:22
http://www.virologyj.com/content/9/1/22
Page 2 of 8Immediate-early genes in HCMV can be silenced in certain
cell types upon infection though, which results in a latent
infection [13]. A latent infection is characterized by the
minimization of viral gene expression and the inhibition of
the assembly and egress of new viral progeny [11]. Latent
infections can reactivate into a lytic infection upon certain
environmental cues, which causes disease and allows viral
spread [1,12].
HCMV infected cells also produce noninfectious envel-
oped particles and dense bodies in addition to infectious
virions as reviewed in Kalejta (2008) [12]. Noninfectious
enveloped particles are similar to infectious virions in that
they contain a nearly an identical assortment of envelope,
tegument, and capsid proteins, but they lack the double-
stranded viral genome within the icosahedral capsid [14].
Dense bodies on the other hand are enveloped tegument
proteins that lack capsids and are primarily composed of
the viral pp65 protein [14]. The significance of the nonin-
fectious enveloped particles and dense bodies is not
known in wild-type strains of HCMV [14].
Tegument structure and function
A possible target for novel antiviral treatments is the
HCMV proteins that localize to the tegument. As men-
tioned, the tegument in HCMV is located between the
outer lipid membrane and the icosahedral protein capsid,
which contains the viral genomic double-stranded DNA
[11]. The tegument is generally thought to be unstruc-
tured and amorphous in nature although some structuring
is seen with the binding of tegument proteins to the pro-
tein capsid [15]. The tegument proteins comprise more
than half of the total proteins found within infectious vir-
ions [16]. Tegument proteins are phosphorylated, but the
significance of this and other posttranslational modifica-
tions to these proteins remains largely unexplored [11]. A
common sequence to direct proteins into the tegument
has not been identified through either experimental or
bioinformatic approaches [17]. The process of assembling
the viral tegument upon viral egress and disassembly upon
viral entry into cells is largely unknown [17]. However as
reviewed in Kalejta (2008), phosphorylation, subcellular
localization to the assembly site, and interaction with cap-
sids or the cytoplasmic tails of envelope proteins, likely
facilitate the incorporation of proteins into the HCMV
tegument [12].
As mentioned above, virions gain entry into a cell
through a membrane fusion event involving the outer
membrane of the cell and the lipid membrane of virions.
The entry of the tegument proteins as well as the DNA-
containing protein capsid upon viral entry occurs after the
fusion of these two membranes [11]. Upon release into the
cytoplasm, tegument proteins become functionally active,
w h e r et h e yp l a yi m p o r t a n tr o l e si na l ls t a g e so ft h ev i r a l
life cycle, including, viral entry, gene expression, immune
evasion, assembly, and egress [1,11]. There are several
tegument proteins that are of particular interest due to the
role (elucidated below) that they play in the HCMV repli-
cation cycle, including pp65, pp71, pp150, and pp28.
Tegument protein pp65
P p 6 5i st h em o s ta b u n d a n tt e g u m e n tp r o t e i na n dt h e
major constituent of extracellular virus particles [18].
However, pp65 is not essential for the production of new
infectious virus particles as evidenced in strains that lack
the pp65 gene [18] which can still replicate in culture.
Pp65 is the major tegument protein responsible for modu-
lating/evading the host cell immune response during
HCMV infections [19]. As reviewed in Kalejta (2008),
pp65 is implicated in counteracting both innate and adap-
tive immune responses during HCMV infections [12].
pp65’s role in immune evasion is largely attributable to its
targeting of both humoral and cellular immunity as well as
serving as the dominant target antigen of cytotoxic T lym-
phocytes [19]. It has been demonstrated that pp65 not
only prevents immediate-early proteins from being recog-
nized by components of the immune system, but it also
inhibits the synthesis of the various components involved
in the host cell’s immune response [20]. One of the ways
in which pp65 counteracts adaptive immunity is through
its enzymatic kinase activity [21]. It was shown that pp65
mediates the phosphorylation of viral immediate-early
proteins, which blocks their presentation to the major his-
tocompatibility complex class I molecules [22]. The kinase
activity of pp65 has also been implicated in causing the
degradation of the alpha chain in the major histocompat-
ibility class II cell surface receptor, HLA-DR, via an accu-
mulation of HLA class II molecules in the lysosome [20].
Furthermore, several studies have presented evidence that
pp65 is involved in mediating a decrease in the expression
of major histocompatibility complex class II molecules
[20]. This is significant in that major histocompatibility
complex class I and II molecules are responsible for lym-
phocyte recognition and antigen presentation with class I
molecules presenting to cytotoxic T lymphocytes CD8+
and class II molecules to helper T lymphocytes CD4+ [20].
Another pivotal role that pp65 has in immune evasion
during HCMV infections is through the inhibition of nat-
ural killer cell cytotoxicity [23]. Specifically, it was shown
that pp65 can act as an antagonistic ligand that can bind
to the NKp30 activating receptor to protect the killing of
infected cells as well as interfere with the ability of NKp30
to cross-talk between other natural killer cells and dendri-
tic cells [23,24].
Finally, pp65 has been shown to attenuate the interferon
response [25]. It is thought that pp65 is involved in down
modulating beta interferon and a number of chemokines,
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of interferon genes in infections with a strain lacking the
pp65 protein [25].
Thus, the role that pp65 has in immune evasion in
HCMV infections is to prevent infected cells from being
destroyed by the immune system. Furthermore, it has
been shown to protect infected cells from the immune
response by binding to components of the immune sys-
tem, thereby inhibiting their activation [24].
Tegument protein pp71
Pp71, by comparison, plays an important role in the
activation of immediate-early gene expression at the
start of the lytic replication cycle [26]. Although this
protein is not absolutely essential, it is necessary for effi-
cient viral replication as reviewed in Kalejta (2008) [12].
A proposed mechanism for how pp71 activates viral
gene expression is by neutralizing the effects of the cel-
lular Daxx protein, which is recruited to promoters by
DNA-binding transcription factors, resulting in the
repression of transcription [27]. Pp71 can bind to two
inherent domains on Daxx and induce its proteasomal
degradation [28]. Additionally, it was demonstrated that
pp71 increases the infectivity of viral genomic DNA
when transfected into cultured cells [29].
Recently though, pp71 has also been implicated in
immune evasion, similar to pp65, by disrupting the major
cell surface expression of components of the immune
response [30]. Specifically, pp71 appears to target the cell
surface receptors of major histocompatibility complex
class I proteins by slowing their intracellular transport
[30]. This limits the ability of infected cells to display viral
antigens to the immune system and prevents recognition
by cytotoxic T lymphocytes.
Tegument proteins pp150 and pp28
Pp150 and pp28 are highly immunogenic and play roles in
the assembly and egress of virus particles. Both of these
tegument proteins play very similar roles, but have some
distinct functions. pp150, the second most abundant tegu-
ment protein behind pp65, is necessary to incorporate
nucleocapsids into virus particles [16]. Pp150 is essential
for maintaining the stability of the cytoplasmic capsids
and directing their movement [1,31].
Pp150 also plays a role in the reorganization of the cyto-
plasmic assembly compartment during virion assembly
[31]. The process of virion assembly in HCMV has been
reviewed in Kalejta (2008) [12]. After the viral genome and
late genes are expressed, capsid formation and DNA
packaging into the preformed capsids begins to occur in
the nucleus. Capsids acquire a primary envelope when
they bud through the inner nuclear membrane into the
perinuclear space, which they lose upon budding through
the outer nuclear membrane into the cytoplasm. The
capsids then bud into Golgi apparatus-derived vesicles and
obtain their final envelope. When these vesicles fuse with
the cell membrane, the enveloped virion is released. Pp28
is largely responsible for the cytoplasmic envelopment of
tegument proteins and capsids in HCMV during the
assembly and egress process [12,32].
Tegument protein subcellular localization
As illustrated, the tegument proteins play important roles
in all stages of the viral life cycle, including, viral entry,
gene expression, immune evasion, assembly, and egress
[11]. However, the subcellular localization of the tegument
proteins after their release into the cytoplasm at the begin-
ning stage of infection has not been fully elucidated. This
is especially true for the localization of the tegument pro-
teins when they are expressed individually or in combina-
tions without the rest of the HCMV virion. Furthermore,
the structure of the tegument itself is not known, and the
process of assembling the tegument upon viral egress, as
well as the disassembly of the tegument upon viral entry
into cells, is poorly understood [17]. Therefore, the objec-
tive of this research was to determine the subcellular loca-
lization of the primary tegument proteins pp65, pp71,
pp150, and pp28, after transfection of plasmid DNA
expressing each protein as a fluorescent protein fusion.
Since these tegument proteins play pivotal roles in several
stages of the viral life cycle, knowledge of where and the
mechanism of how these proteins localize upon release
could be fundamental in the development of effective,
novel antiviral treatments for this widespread human
pathogen, which would have great therapeutic value for
immunocompromised individuals.
When HCMV virions fuse with the membrane of host
cells, some tegument proteins remain in the cytoplasm,
while others migrate to the nucleus of the cell [33]. Other
tegument proteins will remain tightly associated to the
nucleocapsids, and mediate their delivery to the nuclear
pore complex via the microtubule assembly as reviewed in
Kalejta (2008) [12]. Several tegument proteins though will
have a specific localization within the cell depending on
the stage of the lytic cycle.
In the early stage of infection, pp65 tends to indepen-
dently migrate to the nucleoli of the cell [34]. The localiza-
tion of pp65 to the nucleoli suggests a functional
relationship between the localization of pp65 and the
development of the lytic cycle of HCMV [34]. However,
pp65 begins to migrate to the cytoplasm 48 h into the lytic
cycle with nuclear pore complex becoming devoid of the
protein [35]. This migration appears to be mediated by
cyclin-dependent kinase activity and a Crm1 exporter [36].
Pp71, by comparison, has a similar localization pattern
as pp65 during the lytic cycle of HCMV infections. The
subcellular localization of pp71 upon viral entry is to the
nucleus of the host cell [33]. This localization appears to
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infection [37]. During the later stages of infection, some
pp71 appears to localize subcellularly to both the nucleus
and the cytoplasm [38].
Unlike the subcellular localization of pp65 and pp71,
which appears to be dependent on the stage of the lytic
life cycle of HCMV, the localization of pp150 has not
been well-defined. Some studies have suggested that the
subcellular localization of pp150 initially when it associ-
ates with the viral nucleocapsids is to the nucleus, while
other studies suggest that it is to the cytoplasm [39,40].
The subcellular localization of pp28 on the other hand
appears to be to specific cytoplasmic compartments
[41]. This localization appears to be essential for the
production of viral progeny, since it is localized at the
site of final envelopment [41].
Fluorescence proteins as localization tags
The development of fluorescent protein molecules to act
as localization tags for subcellular components has revolu-
tionized the biomedical sciences [42]. The first instance
occurred when Aequorea victoria jellyfish wild-type green
fluorescent protein (GFP) was used to highlight sensory
neurons in the nematode [43]. Fluorescence is such a
powerful tool in that it allows one to distinguish and iden-
tify cellular components that are either too small or lack
little contrast with the background with traditional micro-
scopy techniques. The wild-type green fluorescent protein
molecule was modified to yield different variants due to its
complex emission spectrum [44]. Nonetheless, extensive
research has occurred in recent years to produce new and
improved fluorescent tags that are brighter, cover a broad
spectral range, and also exhibit enhanced photostability,
reduced oligomerization, pH insensitivity, and faster
maturation rates [42].
Due to the success of various fluorescent protein mole-
cules being used as tags to assess the subcellular localiza-
tion and of many cellular and viral proteins, several
distinct fluorescent protein molecules were utilized in this
experiment to identify the subcellular localization of
HCMV tegument proteins pp65, pp71, pp150, and pp28,
respectively [44]. The fluorescent tegument protein fusions
were constructed previously by inserting the open reading
frame of each tegument protein into a plasmid containing
a fluorescence gene so that the two protein coding regions
are in-frame and produce a fusion protein (Pizzorno et al.,
unpublished data). After the plasmid and tegument pro-
teins undergo restriction digests, the resultant sticky ends
fuse to form the fluorescently labeled tegument protein
plasmid. The fluorescent tegument protein fusions are
identified by transforming them into bacterial cells on a
plate containing a specific antibiotic. Since the plasmid
contains the antibiotic resistance gene, the colonies that
are transformed with the fusion plasmid are able to survive
on the plate. The fusion plasmids are then isolated from
the bacterial colonies that were transformed.
In total, three variant fluorescent proteins (Cyan-blue,
RFP (DsRed2)-red, GFP-green) were used to tag and label
the tegument proteins. Pp65 was tagged with Cyan, pp71
with RFP, and pp150 and pp28 with GFP. The characteri-
zation of each fluorescent protein molecule can be seen in
Table 1. Additionally, the location of the fluorescent tags
on each protein can be seen in Figure 2.
Experimental outline and objectives [45]
As mentioned, the objectives of this study were to identify
the subcellular localization of HCMV tegument proteins
pp65, pp71, pp150, and pp28 to understand how these
proteins interact with the cell and function during the lytic
cycle of HCMV infections. Additionally, identification of
the HCMV tegument protein localization patterns could
assist in the development of a better targeted effective,
novel antiviral treatment of HCMV infections, especially
in immunocompromised individuals. This was accom-
plished through the use of cell culture and microscopy
techniques. The tegument proteins of interest were first
fused to a fluorescence protein (Cyan-blue, RFP-red, GFP-
green), as described to in the previous section, that will
emit/fluoresce when exposed to a certain wavelength of
light. The DNA that encodes these modified tegument
proteins were then transfected into an established human
cell lines (HeLa cells). Confocal microscopy, which is an
imaging technique that is used to increase the optical reso-
lution and contrast of photographs obtained through a
microscope, was then utilized to determine the subcellular
localization of each tegument protein within the trans-
fected cells by noting where the Cyan, RFP, or GFP mole-
cule fluoresces to reconstruct three-dimensional structures
of the obtained images. Additionally, the images obtained
from the fluorescence tags were compared and overlaid
with images obtained by concurrently staining with DAPI
or Hoechst 33342, which are fluorescent stains that have a
Table 1 Characterization of the fluorescent molecules used to tag HCMV tegument proteins pp65, pp71, pp150, and
pp28
Fluorescent Molecule Tegument Protein(s) Labeled Excitation Peak (nm) Emission Peak (nm) Brightness Photostability pKa
Cyan pp65 433/445 475/503 13 64 4.7
RFP pp71 584 607 12.5 8.7 4.5
GFP pp150 and pp28 488 507 34 174 6.0
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nucleus of cells, this allowed for a definitive identification
of where these tegument proteins localize subcellularly in
transfected cells.
There were three distinct series of steps in determining
the localization of the tegument proteins. The localization
of the tegument proteins were first identified in fixed cells
that were transfected with plasmids containing the tegu-
ment proteins of interest. Since the localization of each
protein may be affected by the presence or absence of
other tegument proteins, a series of transfections occurred,
including the tegument proteins by themselves and a com-
bination of the different tegument proteins of interest.
Since we have three different fluorescence tags, we were
able to observe the localization of three tegument proteins
in a single cell. The localization patterns in the fixed cells
were then compared to the same series of transfections in
live cells to acquire more accurate observations of the
localization patterns as well as to rule out the possibility
that artifacts of the fixation process may have affected the
subcellular localization patterns of the tegument proteins.
Summary of results [45]
It was shown via fluorescent confocal microscopy that the
localization of each tegument protein was independent of
each other, and that live-cell imaging experiments gave
better results than fixed cell imaging experiments. Further-
more, the subcellular localization of pp71 and pp150
(nucleus), and pp28 (cytoplasm) were identical to what
occurs in a typical HCMV lytic infection, suggesting a
strong correlation between localization and function. The
most significant piece of information that can be drawn
from this experiment, though, concerns that subcellular
localization pattern that was observed for pp65. In the
early stage of a normal HCMV infection, pp65 tends to
independently migrate to the nucleoli of the cell [34]. This
localization to the nucleoli suggests a functional relation-
ship between the localization of pp65 and the development
of the lytic cycle of HCMV [34]. In accordance with pre-
vious experiments, it was hypothesized that pp65 would
subcellularly localize to the nucleus of the cell. However, it
was seen that pp65 localizes to the cytoplasm of the trans-
fected HeLa cells.
The observed localization pattern of pp65 suggests that
something else in the HCMV virion, most likely another
tegument protein, is crucial for pp65 to localize to the
nucleus of a host cell in the early stages of infection.
Moreover, the localization of pp65 to the nucleoli in the
early stages of infection suggests a functional relationship
between the localization of pp65 and the development of
the lytic cycle of HCMV [24]. This implies that if a novel,
antiviral treatment could target the other molecule in the
HCMV virion that is required to assist pp65 to get into
the nucleus of the host cell, HCMV infections and its
devastating effects, especially in immunocompromised
individuals, could be alleviated. This new data suggests
that a potential effective, novel, antiviral treatment for
HCMV infections could be synthesized from inhibiting
the localization of pp65 to the nucleus of the cell in the
early stages of infection.
The results that pp65 does not localize to the nucleus
are interesting, since it is known that pp65 has a bipartite
nuclear localization signal [46]. This implies that the
mechanism by which the other molecule within the
HCMV virion that is necessary for pp65 nuclear localiza-
tion during the initial stages of the lytic infection is to
expose the pp65 nuclear localization signal. It is known
that proteins or other molecules with nuclear localization
signals do not localize to the nucleus until the signal is
exposed and recognized by an importin protein. Thus,
the other molecule within the HVMC virion may bind to
pp65, which yields a conformational change in pp65,
thereby, exposing its nuclear localization signal to impor-
tin proteins during the early stages of the lytic cycle.
Thus, a novel antiviral treatment could target the other
molecule in the HCMV virion, and prevent pp65 from
getting into the nucleus; subsequently inhibiting the
HCMV lytic infection. This research has increased our
understanding of HCMV lytic infections as well as identi-
fies a potential target for a novel, antiviral treatment.
Figure 2 Fluorescently labeled HCMV tegument protein constructs.
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